In a public-private partnership between the Sidney Kimmel Cancer Center (SKCC) at Thomas Jefferson University and ICV, a model that has never been done before in health sciences, we are putting people with capital on the front lines to wipe out some of the world’s deadliest diseases.
ICV will provide full transparency. Every quarter, ICV and select donors will sit with the SKCC research team to review progress in real-time.
What matters. How can we make the most impact with the resources available. What legacy will we leave.
Join us as we empower researchers in the fight against prostate cancer, as part of the Cancer Breakthroughs Fund.
Karen Knudsen, PhD, is Director of the Sidney Kimmel Cancer Center at Thomas Jefferson University and the Hilary Koprowski Chair of the Department of Cancer Biology of the Sidney Kimmel Medical College of Thomas Jefferson University. Jefferson has been a Philadelphia area leader in oncology research, patient treatment and cancer education services for almost 25 years. Initially a single cancer center with a staff of 30, today the Sidney Kimmel Cancer Center (SKCC) at Jefferson includes 32 hospital and practice member institutions staffed by hundreds of oncology researchers and physicians from around the globe. Dr. Knudsen is an expert in the molecular basis of hormone-dependent cancer development and progression, with a special focus on developing means to prevent or treat lethal prostate cancers. Dr. Knudsen’s research interests are dedicated to understanding the mechanisms by which genetic alterations lead to cancer progression and therapeutic bypass. Her studies identifying tumor suppressor and hormone receptor alterations have uncovered new targets for treating advanced disease, and led to development of innovative, biomarker-driven clinical trials. Dr. Knudsen is the Hilary Koprowski Professor and Chair of Cancer Biology at the Thomas Jefferson University, with joint appointments in the Departments of Urology, Radiation Oncology, and Medical Oncology. Notably, Dr. Knudsen served as the first Vice Provost for Thomas Jefferson University, overseeing and integrating basic and clinical research across all six schools at TJU. She took leave of this post in light of her appointment as Director of the Sidney Kimmel Cancer Center (SKCC). For the NCI-designated center, Dr. Knudsen was appointed in 2015 as Director. Dr. Knudsen has significant experience leading multidisciplinary efforts at SKCC and beyond, having served as Deputy Director for Research, founding Leader of the Prostate Program, and Director of Research for t Medical Oncology. Dr. Knudsen serves on multiple national boards and committees associated with both basic and clinical research, including several for the American Association for Cancer Research, the Endocrine Society, and the Prostate Cancer Foundation. She was a Senior Editor for Cancer Research from 2007-2013, is an Associate Editor for Endocrine-Related Cancer, and sits on the editorial boards of Molecular Cancer Therapeutics, the American Journal of Pathology, Molecular Endocrinology, and Oncogene. Most recently, Dr. Knudsen was appointed Editor-in-Chief of Molecular Cancer Research by AACR.
Philanthropy: Love of Humankind
At the end of the day, at the end of our lives, we will ask ourselves whether we could have done more for the health and well-being of the planet, of humanity and all living things. Leverage your charitable giving to create systemic change with ICV’s Catalytic Philanthropy.
ICV Group, Inc. is recognized as a tax-exempt public charity as defined by the Internal Revenue Code (IRC) Sections 501(c)(3) and eligible to receive tax-deductible charitable contributions under IRC Section 170 and qualified to receive tax deductible bequests, devises, transfers or gifts under Section 2055, 2106 or 2522 (EIN: 82-2698363).
“I hope to establish the journal as the seat of outstanding basic research related to cancer.”
– Karen Knudsen, M.D.